Robert Griffin
Professor
Also affiliated: National Institutes of Health (1995–1998); Arthur D. Little (United States) (1996); Aston University (1988–1993); GlaxoSmithKline (United Kingdom) (2001); National Institute of Environmental Health Sciences (1993–1998); GlaxoSmithKline (United States) (2003–2009); UCB Pharma (United Kingdom) (2013–2020); Takeda (United States) (2017–2024); National Radiological Protection Board (1977–1981); Takeda Oncology (United States) (2023); Takeda (Japan) (2015–2024); Newcastle University (1994–2014)
Radiation Oncology, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Robert Griffin's research focuses on the mechanisms of radiation-induced vascular damage in tumors, particularly in the context of ablative hypofractionated radiotherapy, such as stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS). He investigates how radiation impacts the tumor vasculature and the implications for treatment efficacy. Griffin also has a funded project through the NIH/National Cancer Institute, titled "Cancer and Developing Entrepreneurial Technologies (CADET)," for which he serves as PI and received $300,402. This work suggests an interest in translating cancer research into practical applications or technologies.
His scholarly output includes 285 publications with an h-index of 34 and over 4,800 citations, indicating a significant research impact. Griffin has a history of collaboration with researchers at the University of Arkansas for Medical Sciences, including Samir V. Jenkins (16 shared publications), Azemat Jamshidi‐Parsian (13 shared publications), Ruud P.M. Dings (10 shared publications), and Alan J. Tackett (5 shared publications). His work has touched upon various scientific areas, as evidenced by publications ranging from atmospheric organic aerosols to small-molecule inhibitors for cancer treatment, and consensus guidelines for angiogenesis assays. Griffin leads an active research group and maintains a lab website, underscoring his engagement in ongoing research and mentorship.
Metrics
- h-index: 27
- Publications: 193
- Citations: 3,294
Positions
-
Scientific Director 2008–presentTakeda Oncology DMPK ORCID
-
Professor publications 2024University of Arkansas for Medical Sciences Radiation Oncology, College of Medicine Institutional directory
-
Group Leader 1997–2008GlaxoSmithKline USA DMPK ORCID
-
Staff Fellow 1990–1996National Institute of Environmental Health Sciences Metabolic Disposition ORCID
Selected Publications
-
The future is not always uniform: rethinking radiotherapy through spatial fractionation (2026)
-
Macrocyclic histone deacetylase inhibitor-based near-infrared-responsive ionic nanomedicines for enhanced cancer therapy (2026)
-
Abstract 4785: Thermal regulation of dysbiotic tumor vasculature (2026)
-
Abstract 7625: Development of a blood-based tumor hypoxia detection assay (2026)
-
Modified tumor uptake and biodistribution of nanoparticles coated with small extracellular vesicle membranes derived from distinct tumor cell lines (2026)
-
Pancreatic cancer extracellular vesicles stimulate Schwann cell activation and perineural invasion in vitro via IL-8/CCL2 (2025)
-
Abstract B026: Pancreatic tumor extracellular vesicles induce perineural invasion in vitro via IL- 8/CCL2 (2024)
-
The Radiosurgery Society Working Groups on GRID, LATTICE, Microbeam, and FLASH Radiotherapies: Advancements Symposium and Subsequent Progress Made (2024)
-
Interrogating the Role of Endocytosis Pathway and Organelle Trafficking for Doxorubicin-Based Combination Ionic Nanomedicines (2024)
-
Innovations in Physics, Biology and Clinical Translation of Spatially Fractionated and FLASH Radiotherapy (2024)
-
Bystander Effects in Spatially Fractionated Radiation Therapy: From Molecule To Organism To Clinical Implications (2024)
-
Doxorubicin-Based Ionic Nanomedicines for Combined Chemo-Phototherapy of Cancer (2024)
-
Overview and Recommendations for Prospective Multi-institutional Spatially Fractionated Radiation Therapy Clinical Trials (2023)
-
Cationic Porphyrin-Based Ionic Nanomedicines for Improved Photodynamic Therapy (2023)
-
Morphological Effects and In Vitro Biological Mechanisms of Radiation-Induced Cell Killing by Gold Nanomaterials (2023)
Federal Grants 1 $300,402 total
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- Detection of hypoxia markers in tumor exosomes using Raman spectroscopy University of Arkansas at Fayetteville Principal Investigator
- Functional optical biomarkers of response to therapy in head and neck squamous cell carcinoma- Resubmission Arkansas Economic Development Commission via National Science Foundation Principal Investigator
- Improvement of cellular immunotherapy during dysbiosis NIH/Nat. Cancer Institute Principal Investigator
- RII Track-1: Arkansas ASSET Initiative III - Continuation Y5 - Continuation National Science Foundation via Arkansas Economic Development Commission Principal Investigator
- Physiological Factors in Hyperthermia NIH Principal Investigator
- Determination of functional and molecular biomarkers of treatment resistance with multimodal optical spectroscopy- Resubmission NIH/Nat. Cancer Institute via University of Arkansas at Fayetteville Co-Investigator
- Preventing immune system dysregulation during deep-space missions by Tocofexol, a modified isomer of vitamin E - AA request National Aeronautics & Space Administration via Arkansas Space Grant Consortium Principal Investigator
- CASE Year 5 support for Dr. Jamshidi-Parsian Arkansas Economic Development Commission Principal Investigator
- Targeting solid-tumor vasculature with co-encapsulated arsenic- and platinum-based nanobins NIH/Nat. Cancer Institute via University of Kentucky Research Foundation Principal Investigator
- EPSCoR - CASE Summer National Science Foundation via Arkansas Economic Development Commission Principal Investigator
- Studies of Endothelial Dysfunction under Simulated Space Environment National Aeronautics & Space Administration via Arkansas Space Grant Consortium Co-Principal Investigator
- Photoswitchable nanoprobes for in vivo flow cytometry NIH Co-Investigator
- Improvement of cellular immunotherapy during dysbiosis- Resubmission NIH Co-Investigator
- Investigating the role of metabolic rewiring in breast tumor innervation NIH/Nat. Cancer Institute via University of Arkansas at Fayetteville Principal Investigator
- Advancing Breast Cancer Treatment through Suppression of Chemo-Resistance UAMS Executive Breast Committee Principal Investigator
- Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
- Study of anti-angiogenesis enhanced radiotherapy NIH Principal Investigator
Collaboration Network
Top Collaborators
- Hypoxia-derived exosomes induce putative altered pathways in biosynthesis and ion regulatory channels in glioblastoma cells
- Label-Free Raman Spectroscopy Reveals Signatures of Radiation Resistance in the Tumor Microenvironment
- Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems
- Sample storage conditions induce post-collection biases in microbiome profiles
- Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking
Showing 5 of 19 shared publications
- Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization
- Galectins as Molecular Targets for Therapeutic Intervention
- Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice
- Hypoxia-derived exosomes induce putative altered pathways in biosynthesis and ion regulatory channels in glioblastoma cells
- Mild temperature hyperthermia and radiation therapy: Role of tumour vascular thermotolerance and relevant physiological factors
Showing 5 of 17 shared publications
- Glutamine drives glutathione synthesis and contributes to radiation sensitivity of A549 and H460 lung cancer cell lines
- Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice
- Hypoxia-derived exosomes induce putative altered pathways in biosynthesis and ion regulatory channels in glioblastoma cells
- Mild temperature hyperthermia and radiation therapy: Role of tumour vascular thermotolerance and relevant physiological factors
- Tumor-Endothelial Cell Three-dimensional Spheroids: New Aspects to Enhance Radiation and Drug Therapeutics
Showing 5 of 17 shared publications
- Role of miR-2392 in driving SARS-CoV-2 infection
- Spatially Fractionated Radiation Induces Cytotoxicity and Changes in Gene Expression in Bystander and Radiation Adjacent Murine Carcinoma Cells
- Microbeam Radiation Therapy Alters Vascular Architecture and Tumor Oxygenation and is Enhanced by a Galectin-1 Targeted Anti-Angiogenic Peptide
- Prevention and Mitigation of Acute Death of Mice after Abdominal Irradiation by the Antioxidant N-Acetyl-cysteine (NAC)
- Spatially fractionated radiotherapy (GRID) using helical tomotherapy
Showing 5 of 9 shared publications
- Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice
- Hypoxia-derived exosomes induce putative altered pathways in biosynthesis and ion regulatory channels in glioblastoma cells
- Modulation of dietary methionine intake elicits potent, yet distinct, anticancer effects on primary versus metastatic tumors
- MSC exosome-mediated cardioprotection in ischemic mouse heart comparative proteomics of infarct and peri-infarct areas
- Modifying Dendritic Cell Activation with Plasmonic Nano Vectors
Showing 5 of 9 shared publications
- Indirect Tumor Cell Death After High-Dose Hypofractionated Irradiation: Implications for Stereotactic Body Radiation Therapy and Stereotactic Radiation Surgery
- Photothermal nanodrugs: potential of TNF-gold nanospheres for cancer theranostics
- Nanoparticle Delivered Vascular Disrupting Agents (VDAs): Use of TNF-Alpha Conjugated Gold Nanoparticles for Multimodal Cancer Therapy
- Tumor-Endothelial Cell Three-dimensional Spheroids: New Aspects to Enhance Radiation and Drug Therapeutics
- Microbeam Radiation Therapy Alters Vascular Architecture and Tumor Oxygenation and is Enhanced by a Galectin-1 Targeted Anti-Angiogenic Peptide
Showing 5 of 8 shared publications
- Radiation-Induced Vascular Damage in Tumors: Implications of Vascular Damage in Ablative Hypofractionated Radiotherapy (SBRT and SRS)
- Indirect Tumor Cell Death After High-Dose Hypofractionated Irradiation: Implications for Stereotactic Body Radiation Therapy and Stereotactic Radiation Surgery
- Radiobiology of Stereotactic Body Radiation Therapy/Stereotactic Radiosurgery and the Linear-Quadratic Model
- Mild temperature hyperthermia and radiation therapy: Role of tumour vascular thermotolerance and relevant physiological factors
- Is Indirect Cell Death Involved in Response of Tumors to Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy?
Showing 5 of 8 shared publications
- High dose bystander effects in spatially fractionated radiation therapy
- Spatially Fractionated Radiation Induces Cytotoxicity and Changes in Gene Expression in Bystander and Radiation Adjacent Murine Carcinoma Cells
- Overview and Recommendations for Prospective Multi-institutional Spatially Fractionated Radiation Therapy Clinical Trials
- History and current perspectives on the biological effects of high-dose spatial fractionation and high dose-rate approaches: GRID, Microbeam & FLASH radiotherapy
- Spatially fractionated radiotherapy (GRID) using helical tomotherapy
Showing 5 of 8 shared publications
- The Technical and Clinical Implementation of LATTICE Radiation Therapy (LRT)
- Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy
- Photon GRID Radiation Therapy: A Physics and Dosimetry White Paper from the Radiosurgery Society (RSS) GRID/LATTICE, Microbeam and FLASH Radiotherapy Working Group
- Overview and Recommendations for Prospective Multi-institutional Spatially Fractionated Radiation Therapy Clinical Trials
- Practice Patterns of Spatially Fractionated Radiation Therapy: A Clinical Practice Survey
Showing 5 of 7 shared publications
- Glutamine drives glutathione synthesis and contributes to radiation sensitivity of A549 and H460 lung cancer cell lines
- Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice
- Microbeam Radiation Therapy Alters Vascular Architecture and Tumor Oxygenation and is Enhanced by a Galectin-1 Targeted Anti-Angiogenic Peptide
- Indocyanine green enhanced near‐infrared laser treatment of murine mammary carcinoma
- Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking
Showing 5 of 6 shared publications
- Photothermal nanodrugs: potential of TNF-gold nanospheres for cancer theranostics
- Exosome Traceability and Cell Source Dependence on Composition and Cell-Cell Cross Talk
- Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems
- 3D cultures for modeling nanomaterial-based photothermal therapy
- Modifying Dendritic Cell Activation with Plasmonic Nano Vectors
Showing 5 of 6 shared publications
- The Technical and Clinical Implementation of LATTICE Radiation Therapy (LRT)
- Photon GRID Radiation Therapy: A Physics and Dosimetry White Paper from the Radiosurgery Society (RSS) GRID/LATTICE, Microbeam and FLASH Radiotherapy Working Group
- Overview and Recommendations for Prospective Multi-institutional Spatially Fractionated Radiation Therapy Clinical Trials
- Practice Patterns of Spatially Fractionated Radiation Therapy: A Clinical Practice Survey
- An International Consensus on the Design of Prospective Clinical–Translational Trials in Spatially Fractionated Radiation Therapy for Advanced Gynecologic Cancer
Showing 5 of 6 shared publications
- Indirect Tumor Cell Death After High-Dose Hypofractionated Irradiation: Implications for Stereotactic Body Radiation Therapy and Stereotactic Radiation Surgery
- Radiobiology of Stereotactic Body Radiation Therapy/Stereotactic Radiosurgery and the Linear-Quadratic Model
- Is Indirect Cell Death Involved in Response of Tumors to Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy?
- Reoxygenation and Repopulation of Tumor Cells after Ablative Hypofractionated Radiotherapy (SBRT and SRS) in Murine Tumors
- Preferential Tumor Vascular Damage Is the Common Antitumor Mechanism of High-Dose Hypofractionated Radiation Therapy: SABR, Spatially Fractionated Radiation Therapy, and FLASH Radiation Therapy
- Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems
- Sample storage conditions induce post-collection biases in microbiome profiles
- Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking
- Modifying Dendritic Cell Activation with Plasmonic Nano Vectors
- Dysbiotic stress increases the sensitivity of the tumor vasculature to radiotherapy and c-Met inhibitors
- The Technical and Clinical Implementation of LATTICE Radiation Therapy (LRT)
- Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy
- Practice Patterns of Spatially Fractionated Radiation Therapy: A Clinical Practice Survey
- An International Consensus on the Design of Prospective Clinical–Translational Trials in Spatially Fractionated Radiation Therapy for Advanced Gynecologic Cancer
- The Radiosurgery Society Working Groups on GRID, LATTICE, Microbeam, and FLASH Radiotherapies: Advancements Symposium and Subsequent Progress Made
Similar Researchers
Based on overlapping research topics